Click for best price
Metabolic Disease Drugs Market Size, Share 2023
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disease Drugs. This report contains market size and forecasts of Metabolic Disease Drugs in global, including the following market information:
Global Metabolic Disease Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Metabolic Disease Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Glycogen Metabolism Disease Drug Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Metabolic Disease Drugs include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Beohrigher Ingelheim, KOWA, Kythera, Fuji yakuhin and LG Life Science, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Metabolic Disease Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metabolic Disease Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Metabolic Disease Drugs Market Segment Percentages, by Type, 2022 (%)
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Global Metabolic Disease Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Metabolic Disease Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Global Metabolic Disease Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Metabolic Disease Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metabolic Disease Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Metabolic Disease Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Metabolic Disease Drugs, market overview.
Chapter 2: Global Metabolic Disease Drugs market size in revenue.
Chapter 3: Detailed analysis of Metabolic Disease Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metabolic Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Metabolic Disease Drugs Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
66 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Metabolic Disease Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metabolic Disease Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metabolic Disease Drugs Overall Market Size
2.1 Global Metabolic Disease Drugs Market Size: 2022 VS 2029
2.2 Global Metabolic Disease Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Metabolic Disease Drugs Players in Global Market
3.2 Top Global Metabolic Disease Drugs Companies Ranked by Revenue
3.3 Global Metabolic Disease Drugs Revenue by Companies
3.4 Top 3 and Top 5 Metabolic Disease Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Metabolic Disease Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Metabolic Disease Drugs Players in Global Market
3.6.1 List of Global Tier 1 Metabolic Disease Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Metabolic Disease Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Metabolic Disease Drugs Market Size Markets, 2022 & 2029
4.1.2 Glycogen Metabolism Disease Drug
4.1.3 Lipid Metabolism Disease Drug
4.1.4 Amino Acid Metabolism Drug
4.1.5 Other
4.2 By Type - Global Metabolic Disease Drugs Revenue & Forecasts
4.2.1 By Type - Global Metabolic Disease Drugs Revenue, 2018-2023
4.2.2 By Type - Global Metabolic Disease Drugs Revenue, 2024-2029
4.2.3 By Type - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Metabolic Disease Drugs Market Size, 2022 & 2029
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.2 By Application - Global Metabolic Disease Drugs Revenue & Forecasts
5.2.1 By Application - Global Metabolic Disease Drugs Revenue, 2018-2023
5.2.2 By Application - Global Metabolic Disease Drugs Revenue, 2024-2029
5.2.3 By Application - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Metabolic Disease Drugs Market Size, 2022 & 2029
6.2 By Region - Global Metabolic Disease Drugs Revenue & Forecasts
6.2.1 By Region - Global Metabolic Disease Drugs Revenue, 2018-2023
6.2.2 By Region - Global Metabolic Disease Drugs Revenue, 2024-2029
6.2.3 By Region - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Metabolic Disease Drugs Revenue, 2018-2029
6.3.2 US Metabolic Disease Drugs Market Size, 2018-2029
6.3.3 Canada Metabolic Disease Drugs Market Size, 2018-2029
6.3.4 Mexico Metabolic Disease Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Metabolic Disease Drugs Revenue, 2018-2029
6.4.2 Germany Metabolic Disease Drugs Market Size, 2018-2029
6.4.3 France Metabolic Disease Drugs Market Size, 2018-2029
6.4.4 U.K. Metabolic Disease Drugs Market Size, 2018-2029
6.4.5 Italy Metabolic Disease Drugs Market Size, 2018-2029
6.4.6 Russia Metabolic Disease Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Metabolic Disease Drugs Market Size, 2018-2029
6.4.8 Benelux Metabolic Disease Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Metabolic Disease Drugs Revenue, 2018-2029
6.5.2 China Metabolic Disease Drugs Market Size, 2018-2029
6.5.3 Japan Metabolic Disease Drugs Market Size, 2018-2029
6.5.4 South Korea Metabolic Disease Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Metabolic Disease Drugs Market Size, 2018-2029
6.5.6 India Metabolic Disease Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Metabolic Disease Drugs Revenue, 2018-2029
6.6.2 Brazil Metabolic Disease Drugs Market Size, 2018-2029
6.6.3 Argentina Metabolic Disease Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Metabolic Disease Drugs Revenue, 2018-2029
6.7.2 Turkey Metabolic Disease Drugs Market Size, 2018-2029
6.7.3 Israel Metabolic Disease Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Metabolic Disease Drugs Market Size, 2018-2029
6.7.5 UAE Metabolic Disease Drugs Market Size, 2018-2029
7 Metabolic Disease Drugs Companies Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Metabolic Disease Drugs Major Product Offerings
7.1.4 Merck Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Metabolic Disease Drugs Major Product Offerings
7.2.4 Novartis Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Metabolic Disease Drugs Major Product Offerings
7.3.4 Takeda Pharmaceutical Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.3.5 Takeda Pharmaceutical Key News & Latest Developments
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Metabolic Disease Drugs Major Product Offerings
7.4.4 Astra Zeneca Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.4.5 Astra Zeneca Key News & Latest Developments
7.5 Beohrigher Ingelheim
7.5.1 Beohrigher Ingelheim Company Summary
7.5.2 Beohrigher Ingelheim Business Overview
7.5.3 Beohrigher Ingelheim Metabolic Disease Drugs Major Product Offerings
7.5.4 Beohrigher Ingelheim Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.5.5 Beohrigher Ingelheim Key News & Latest Developments
7.6 KOWA
7.6.1 KOWA Company Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Metabolic Disease Drugs Major Product Offerings
7.6.4 KOWA Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.6.5 KOWA Key News & Latest Developments
7.7 Kythera
7.7.1 Kythera Company Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Metabolic Disease Drugs Major Product Offerings
7.7.4 Kythera Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.7.5 Kythera Key News & Latest Developments
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Metabolic Disease Drugs Major Product Offerings
7.8.4 Fuji yakuhin Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.8.5 Fuji yakuhin Key News & Latest Developments
7.9 LG Life Science
7.9.1 LG Life Science Company Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Metabolic Disease Drugs Major Product Offerings
7.9.4 LG Life Science Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.9.5 LG Life Science Key News & Latest Developments
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Metabolic Disease Drugs Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Metabolic Disease Drugs Revenue in Global Market (2018-2023)
7.10.5 Metsubishi Tanabe Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Metabolic Disease Drugs Market Opportunities & Trends in Global Market
Table 2. Metabolic Disease Drugs Market Drivers in Global Market
Table 3. Metabolic Disease Drugs Market Restraints in Global Market
Table 4. Key Players of Metabolic Disease Drugs in Global Market
Table 5. Top Metabolic Disease Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Metabolic Disease Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Metabolic Disease Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Metabolic Disease Drugs Product Type
Table 9. List of Global Tier 1 Metabolic Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metabolic Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Metabolic Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Metabolic Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Metabolic Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Metabolic Disease Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Metabolic Disease Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Metabolic Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Metabolic Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Metabolic Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Metabolic Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Metabolic Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Merck Company Summary
Table 31. Merck Metabolic Disease Drugs Product Offerings
Table 32. Merck Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Merck Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis Metabolic Disease Drugs Product Offerings
Table 36. Novartis Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis Key News & Latest Developments
Table 38. Takeda Pharmaceutical Company Summary
Table 39. Takeda Pharmaceutical Metabolic Disease Drugs Product Offerings
Table 40. Takeda Pharmaceutical Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Takeda Pharmaceutical Key News & Latest Developments
Table 42. Astra Zeneca Company Summary
Table 43. Astra Zeneca Metabolic Disease Drugs Product Offerings
Table 44. Astra Zeneca Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Astra Zeneca Key News & Latest Developments
Table 46. Beohrigher Ingelheim Company Summary
Table 47. Beohrigher Ingelheim Metabolic Disease Drugs Product Offerings
Table 48. Beohrigher Ingelheim Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Beohrigher Ingelheim Key News & Latest Developments
Table 50. KOWA Company Summary
Table 51. KOWA Metabolic Disease Drugs Product Offerings
Table 52. KOWA Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. KOWA Key News & Latest Developments
Table 54. Kythera Company Summary
Table 55. Kythera Metabolic Disease Drugs Product Offerings
Table 56. Kythera Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Kythera Key News & Latest Developments
Table 58. Fuji yakuhin Company Summary
Table 59. Fuji yakuhin Metabolic Disease Drugs Product Offerings
Table 60. Fuji yakuhin Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Fuji yakuhin Key News & Latest Developments
Table 62. LG Life Science Company Summary
Table 63. LG Life Science Metabolic Disease Drugs Product Offerings
Table 64. LG Life Science Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. LG Life Science Key News & Latest Developments
Table 66. Metsubishi Tanabe Pharma Company Summary
Table 67. Metsubishi Tanabe Pharma Metabolic Disease Drugs Product Offerings
Table 68. Metsubishi Tanabe Pharma Metabolic Disease Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Metsubishi Tanabe Pharma Key News & Latest Developments
List of Figures
Figure 1. Metabolic Disease Drugs Segment by Type in 2022
Figure 2. Metabolic Disease Drugs Segment by Application in 2022
Figure 3. Global Metabolic Disease Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Metabolic Disease Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Metabolic Disease Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Metabolic Disease Drugs Revenue in 2022
Figure 8. By Type - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Metabolic Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Metabolic Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 16. US Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 28. China Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Metabolic Disease Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Metabolic Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Merck Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Takeda Pharmaceutical Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Astra Zeneca Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Beohrigher Ingelheim Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. KOWA Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Kythera Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Fuji yakuhin Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. LG Life Science Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Metsubishi Tanabe Pharma Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
